Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its price target decreased by UBS AG from $535.00 to $500.00 in a research report released on Thursday, www.benzinga.com reports. UBS AG currently has a buy rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other research reports. Morgan Stanley reissued an equal weight rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 23rd. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the company a buy rating in a research note on Monday, August 14th. Leerink Swann reissued an outperform rating and issued a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Oppenheimer Holdings, Inc. reissued a hold rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 14th. Finally, Citigroup Inc. increased their target price on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a buy rating in a research note on Friday, August 4th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $490.03.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 432.72 on Thursday. The firm has a market cap of $45.88 billion, a P/E ratio of 43.41 and a beta of 1.65. The company’s 50 day moving average price is $468.97 and its 200 day moving average price is $447.18. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm’s revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals will post $14.89 EPS for the current year.

WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) PT Lowered to $500.00 at UBS AG” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/24/regeneron-pharmaceuticals-inc-regn-pt-lowered-to-500-00-at-ubs-ag.html.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman P Roy Vagelos sold 1,305 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $470.00, for a total transaction of $613,350.00. Following the transaction, the chairman now directly owns 329,543 shares of the company’s stock, valued at approximately $154,885,210. The disclosure for this sale can be found here. Insiders sold 85,968 shares of company stock valued at $40,699,948 over the last 90 days. 10.40% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fieldpoint Private Securities LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $130,000. Sterling Investment Advisors Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares in the last quarter. FNY Managed Accounts LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $140,000. FNY Partners Fund LP increased its stake in shares of Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 200 shares in the last quarter. Finally, Alpha Windward LLC increased its stake in shares of Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1 shares in the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.